Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1471462

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1471462

Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029

PUBLISHED:
PAGES: 402 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

The vaccines market (including COVID-19 vaccines) is projected to reach USD 94.9 Billion by 2029 from USD 78.0 Billion in 2024, at a CAGR of 4.0% during the forecast period. Similarly the vaccines market (excluding COVID-19 vaccines) is projected to reach USD 80.3 Billion by 2029 from USD 53.0 Billion in 2024, at a CAGR of 8.7% during the forecast period. The vaccines market is driven by several key factors, including increasing global population, rising prevalence of infectious diseases, and growing awareness of preventive healthcare. Technological advancements in vaccine development, coupled with expanding immunization programs worldwide, contribute to market growth.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsBy Technology, By Type, By Disease Indication, By Route of Administration, By End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The conjugate vaccines segment (excluding COVID -19 vaccines) held the dominant share in the vaccines market."

Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, conjugate vaccines and other vaccines. Conjugate vaccines segment dominated the vaccine market in 2023. Robust research and development investments, strategic partnerships, and favorable regulatory environments have further bolstered the prominence of conjugated vaccines, solidifying their position as indispensable tools in the fight against infectious diseases and driving sustained growth in the vaccines market.

"HPV segment (excluding COVID-19 vaccines) accounted for the largest share of the disease indication segment in 2023."

Based on disease indication, the vaccines market (excluding COVID-19 vaccines) is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, RSV, and other disease indications. In 2023, HPV segment dominated the vaccines market. RSV segment is anticipated to grow at significant CAGR during the forecast period of 2024-2028 owing to various factors such as launch of new HPV vaccine and robust products under clinical trials.

"Asia Pacific region is likely to grow at a faster pace in the vaccines market (excluding COVID -19 vaccines)."

The vaccines market (excluding COVID-19 vaccines) region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. The Asia-Pacific region is poised to experience significant growth in the vaccines market due to several key factors such as increasing healthcare expenditure in countries like China, India, and Southeast Asian nations are driving demand for vaccines to combat infectious diseases. Expanding government initiatives aimed at improving vaccination coverage and healthcare infrastructure further stimulate market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4% and Africa -1%

List of Companies Profiled in the Report:

  • GSK plc (UK)
  • Merck & Co., Inc. (US)
  • Pfizer, Inc. (US)
  • Sanofi (France)
  • CSL (Australia)
  • Emergent (US)
  • Johnson & Johnson Services Inc. (US)
  • AstraZeneca (UK)
  • Serum Institute of India Pvt. Ltd. (India)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Panacea Biotec (India)
  • Biological E. Limited (India)
  • Bharat Biotech (India)
  • Novavax (US)
  • Inovio Pharmaceuticals (US)
  • Sinovac (China)
  • Incepta Pharmaceuticals (Bangladesh)
  • Valneva SE (France),
  • VBI Vaccines Inc. (US)
  • Bio Farma (Indonesia)
  • FSUE NPO Microgen (Russia)
  • Zhi fei Biological (China)
  • Indian Immunologicals Ltd (India)

Research Coverage:

This report provides a detailed picture of the vaccine market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, government support and funding for vaccine development), restraints (High cost of vaccine development), opportunities (Rising focus on therapeutic vaccines, Extensive R&D for vaccines and increased investments in clinical trials) and challenges (stringent regulatory processes, product recall) are influencing the growth of vaccines market.
  • Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the vaccines market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market.
  • Pipeline Analysis: Comprehensive information about products under clinical trials.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).
Show more
Product Code: PH 6528

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
    • 2.2.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES
      • 2.2.2.1 Primary research
  • 2.3 MARKET SIZE ESTIMATION
    • FIGURE 3 MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS, 2023
    • 2.3.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • 2.3.2 SEGMENTAL ASSESSMENT
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.4 GROWTH RATE ASSUMPTIONS
    • FIGURE 8 VACCINES MARKET: CAGR PROJECTION (2024-2029)
    • FIGURE 9 VACCINES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ASSESSMENT
  • 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 12 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 16 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 17 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 18 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 19 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 20 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 21 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (EXCLUDING COVID-19 VACCINES)
    • FIGURE 22 GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (INCLUDING COVID-19 VACCINES)

4 PREMIUM INSIGHTS

  • 4.1 VACCINES MARKET OVERVIEW (INCLUDING COVID-19 VACCINES)
    • FIGURE 23 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • 4.2 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)
    • FIGURE 24 LAUNCH OF RSV VACCINES AND STRONG PRODUCT PIPELINE TO DRIVE MARKET
  • 4.3 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY AND COUNTRY, 2023
    • FIGURE 25 US AND CONJUGATE VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2023
  • 4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET (EXCLUDING COVID-19 VACCINES)
    • FIGURE 26 ASIA PACIFIC MARKETS TO REGISTER HIGHEST GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 27 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET
    • TABLE 1 IMPACT ANALYSIS: VACCINES MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Focus on vaccine development and launches
      • 5.2.1.2 Rising prevalence of infectious diseases
    • FIGURE 28 US: INCIDENCE OF TUBERCULOSIS, 2017-2021
      • 5.2.1.3 Increasing immunization programs
      • 5.2.1.4 Advancements in vaccine technology
      • 5.2.1.5 Government support and funding for vaccine development
    • TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2020-2024 (USD MILLION)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of vaccine development
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising focus on therapeutic vaccines
      • 5.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory processes
      • 5.2.4.2 Product recalls
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 29 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER
    • TABLE 3 AVERAGE SELLING PRICE OF PEDIATRIC VACCINES
    • TABLE 4 AVERAGE SELLING PRICE OF ADULT VACCINES
    • 5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE
    • TABLE 5 AVERAGE SELLING PRICE OF CONJUGATE VACCINES
    • TABLE 6 AVERAGE SELLING PRICE OF RECOMBINANT VACCINES
    • TABLE 7 AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES
    • TABLE 8 AVERAGE SELLING PRICE OF LIVE ATTENUATED VACCINES
    • TABLE 9 AVERAGE SELLING PRICE OF TOXOID VACCINES
    • TABLE 10 AVERAGE SELLING PRICE OF M-RNA VACCINES
    • 5.4.3 AVERAGE SELLING PRICE TREND
  • 5.5 TECHNOLOGY ANALYSIS
    • 5.5.1 MRNA VACCINES
    • 5.5.2 DNA TECHNOLOGY
    • 5.5.3 VLP VACCINE TECHNOLOGY
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 30 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE
  • 5.7 PIPELINE ANALYSIS
    • FIGURE 31 VACCINES MARKET: CLINICAL TRIALS, BY PHASE
    • FIGURE 32 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
    • TABLE 11 PIPELINE PRODUCTS UNDER PHASE 2 AND PHASE 3 CLINICAL TRIALS
    • TABLE 12 VACCINE PIPELINE PRODUCTS UNDER PHASE-3 CLINICAL TRIALS FOR RSV
    • 5.7.1 KEY PIPELINE PRODUCTS
    • TABLE 13 KEY PIPELINE VACCINES: GSK PLC
    • TABLE 14 KEY PIPELINE VACCINES: MERCK & CO., INC.
    • TABLE 15 KEY PIPELINE VACCINES: PFIZER INC.
    • TABLE 16 KEY PIPELINE VACCINES: SANOFI S.A.
  • 5.8 ECOSYSTEM/MARKET MAP
    • FIGURE 33 ECOSYSTEM/MARKET MAP
    • TABLE 17 ROLE IN ECOSYSTEM: VACCINES MARKET
  • 5.9 REGULATORY ANALYSIS
    • TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 22 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 23 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 24 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF SUPPLIERS
    • 5.10.4 BARGAINING POWER OF BUYERS
    • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11 PATENT ANALYSIS
    • FIGURE 34 PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013-SEPTEMBER 2023
    • TABLE 25 VACCINES MARKET: INDICATIVE LIST OF PATENTS
  • 5.12 KEY CONFERENCES & EVENTS, 2024-2025
    • TABLE 26 DETAILED LIST OF CONFERENCES & EVENTS
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES
    • 5.13.2 KEY BUYING CRITERIA
    • FIGURE 36 KEY BUYING CRITERIA FOR END USERS

6 VACCINES MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
    • TABLE 27 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 28 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • 6.2 CONJUGATE VACCINES
    • 6.2.1 INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET
    • TABLE 29 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 30 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 31 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 33 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 RECOMBINANT VACCINES
    • 6.3.1 LOW POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET
    • TABLE 34 EXAMPLES OF RECOMBINANT VACCINES
    • TABLE 35 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 36 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 37 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 39 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 INACTIVATED & SUBUNIT VACCINES
    • 6.4.1 EASE OF STORAGE AND TRANSPORTATION TO SUPPORT GROWTH
    • TABLE 40 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
    • TABLE 41 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 42 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 43 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 45 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.5 LIVE ATTENUATED VACCINES
    • 6.5.1 HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO RESTRAIN MARKET
    • TABLE 46 EXAMPLES OF LIVE ATTENUATED VACCINES
    • TABLE 47 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 48 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 49 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 51 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.6 TOXOID VACCINES
    • 6.6.1 RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET
    • TABLE 52 EXAMPLES OF TOXOID VACCINES
    • TABLE 53 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 54 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 55 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 57 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.7 VIRAL VECTOR VACCINES
    • 6.7.1 RISING INVESTMENT IN VACCINE DEVELOPMENT TO DRIVE MARKET
    • TABLE 58 VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 59 NORTH AMERICA: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 60 EUROPE: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 62 LATIN AMERICA: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.8 MRNA VACCINES
    • 6.8.1 INCREASING FOCUS ON MRNA VACCINE DEVELOPMENT TO DRIVE MARKET
    • TABLE 63 MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 64 NORTH AMERICA: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 65 EUROPE: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 67 LATIN AMERICA: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.9 OTHER VACCINES
    • TABLE 68 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 69 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 70 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 72 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)

7 VACCINES MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 73 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 74 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
  • 7.2 MULTIVALENT VACCINES
    • 7.2.1 INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET
    • TABLE 75 EXAMPLES OF MULTIVALENT VACCINES
    • TABLE 76 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 77 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 78 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 80 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 MONOVALENT VACCINES
    • 7.3.1 RISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 81 EXAMPLES OF MONOVALENT VACCINES
    • TABLE 82 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 83 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 84 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 86 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)

8 VACCINES MARKET, BY DISEASE INDICATION

  • 8.1 INTRODUCTION
    • TABLE 87 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 88 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
  • 8.2 PNEUMOCOCCAL DISEASE
    • 8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET
    • TABLE 89 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES
    • TABLE 90 PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 91 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 94 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 INFLUENZA
    • 8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET
    • TABLE 95 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES
    • TABLE 96 INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 97 NORTH AMERICA: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 98 EUROPE: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 100 LATIN AMERICA: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.4 COMBINATION VACCINES
    • 8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET
    • TABLE 101 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES
    • TABLE 102 COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 103 NORTH AMERICA: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 104 EUROPE: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 105 ASIA PACIFIC: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 106 LATIN AMERICA: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.5 HPV
    • 8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET
    • TABLE 107 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES
    • TABLE 108 HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 109 NORTH AMERICA: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 110 EUROPE: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 LATIN AMERICA: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.6 MENINGOCOCCAL DISEASE
    • 8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET
    • TABLE 113 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES
    • TABLE 114 MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 115 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 116 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 118 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.7 HERPES ZOSTER
    • 8.7.1 INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET
    • TABLE 119 HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 120 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 121 EUROPE: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 123 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.8 ROTAVIRUS
    • 8.8.1 GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO PROPEL MARKET
    • TABLE 124 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES
    • TABLE 125 ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 126 NORTH AMERICA: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 127 EUROPE: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 128 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 129 LATIN AMERICA: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.9 MMR
    • 8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND
    • TABLE 130 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES
    • TABLE 131 MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 132 NORTH AMERICA: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 133 EUROPE: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 134 ASIA PACIFIC: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 135 LATIN AMERICA: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.10 VARICELLA
    • 8.10.1 INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
    • TABLE 136 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES
    • TABLE 137 VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 138 NORTH AMERICA: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 139 EUROPE: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 141 LATIN AMERICA: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.11 HEPATITIS
    • 8.11.1 LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET
    • TABLE 142 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES
    • TABLE 143 HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 144 NORTH AMERICA: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 145 EUROPE: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 147 LATIN AMERICA: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.12 DTP
    • 8.12.1 INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET
    • TABLE 148 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES
    • TABLE 149 DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 150 NORTH AMERICA: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 151 EUROPE: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 152 ASIA PACIFIC: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 153 LATIN AMERICA: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.13 POLIO
    • 8.13.1 INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET
    • TABLE 154 POLIO VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 155 NORTH AMERICA: POLIO VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 156 EUROPE: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 157 ASIA PACIFIC: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 158 LATIN AMERICA: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.14 RSV
    • 8.14.1 STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH
    • TABLE 159 RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 160 NORTH AMERICA: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 161 EUROPE: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 162 ASIA PACIFIC: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 163 LATIN AMERICA: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.15 OTHER DISEASE INDICATIONS
    • FIGURE 37 US: NUMBER OF COVID-19 CASES, 2020-2023
    • TABLE 164 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
    • TABLE 165 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 166 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 167 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 168 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 169 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 170 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 173 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 174 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)

9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
    • TABLE 175 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), 2022-2029 (USD MILLION)
    • TABLE 176 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (INCLUDING COVID-19 VACCINES), 2022-2029 (USD MILLION)
  • 9.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
    • 9.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION
    • TABLE 177 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION
    • TABLE 178 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 179 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 180 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 181 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 182 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 ORAL ADMINISTRATION
    • 9.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION
    • TABLE 183 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 184 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 185 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 186 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 187 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.4 OTHER ROUTES OF ADMINISTRATION
    • TABLE 188 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 189 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 190 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 192 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)

10 VACCINES MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 193 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • TABLE 194 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
  • 10.2 ADULT VACCINES
    • 10.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE
    • TABLE 195 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 196 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 197 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 198 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 199 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
  • 10.3 PEDIATRIC VACCINES
    • 10.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET
    • TABLE 200 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 201 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 202 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 203 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 204 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)

11 VACCINES MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 205 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
    • TABLE 206 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)
  • 11.2 NORTH AMERICA
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 38 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
    • TABLE 207 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 208 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 209 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 210 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 211 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 212 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.2.2 US
      • 11.2.2.1 US to dominate North American market
    • TABLE 213 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 214 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 215 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 216 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 217 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 High incidence of infectious diseases to drive market
    • TABLE 218 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 219 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 220 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 221 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 222 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
  • 11.3 EUROPE
    • 11.3.1 EUROPE: RECESSION IMPACT
    • TABLE 223 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 224 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 225 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 226 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 227 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 228 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.3.2 GERMANY
      • 11.3.2.1 Significant R&D investments and growing biotechnology industry to drive market
    • TABLE 229 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 230 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 231 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 232 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Launch of new products and increased funding by government and non-government organizations to drive market
    • TABLE 233 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 234 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 235 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 236 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Favorable government initiatives for mass immunization to drive market
    • TABLE 237 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 238 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 239 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 240 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.3.5 ITALY
      • 11.3.5.1 Higher investments by companies for increased production capacities to drive market
    • TABLE 241 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 242 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 243 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 244 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Rising investments in vaccine development by private organizations to drive market
    • TABLE 245 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 246 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 247 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 248 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 249 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 250 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 251 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 252 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 39 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
    • TABLE 253 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 254 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 255 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 256 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 257 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 258 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Favorable government initiatives to support market growth
    • TABLE 259 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 260 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 261 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 262 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.4.3 SOUTH KOREA
      • 11.4.3.1 Strong government strategies for improved vaccine hubs to drive market
    • TABLE 263 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 264 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 265 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 266 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.4.4 CHINA
      • 11.4.4.1 China to hold largest share in APAC vaccines market
    • TABLE 267 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 268 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 269 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 270 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.4.5 INDIA
      • 11.4.5.1 Increasing government initiatives and development of new and improved vaccines to drive market
    • TABLE 271 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 272 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 273 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 274 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.4.6 REST OF ASIA PACIFIC
    • TABLE 275 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 276 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 277 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 278 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
  • 11.5 LATIN AMERICA
    • 11.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 279 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 280 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 281 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 282 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 283 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 284 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.5.2 BRAZIL
      • 11.5.2.1 Rising focus on immunization programs to drive market
    • TABLE 285 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 286 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 287 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 288 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.5.3 MEXICO
      • 11.5.3.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth
    • TABLE 289 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 290 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 291 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 292 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.5.4 REST OF LATIN AMERICA
    • TABLE 293 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 294 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 295 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 296 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • 11.6.2 MIDDLE EAST
      • 11.6.2.1 Increasing prevalence of infectious diseases to drive market
    • TABLE 297 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 298 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 299 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)
    • TABLE 300 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 301 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)
    • 11.6.3 AFRICA
      • 11.6.3.1 Availability of funds and grants from developed economies to drive market
    • TABLE 302 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)
    • TABLE 303 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 304 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
    • TABLE 305 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY STRATEGIES/RIGHT TO WIN
    • FIGURE 40 STRATEGIES ADOPTED BY MAJOR PLAYERS IN VACCINES MARKET
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 41 REVENUE SHARE ANALYSIS, 2021-2023
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
    • TABLE 306 VACCINES MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 43 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 12.5.5 COMPANY FOOTPRINT
    • TABLE 307 TYPE FOOTPRINT
    • TABLE 308 REGIONAL FOOTPRINT
  • 12.6 COMPANY EVALUATION MATRIX: START-UP/SME PLAYERS
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 44 VACCINES MARKET: COMPANY EVALUATION MATRIX (START-UP/SME PLAYERS), 2023
    • 12.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES
    • TABLE 309 VACCINES MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 310 VACCINES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 12.7 COMPETITIVE SCENARIOS
    • 12.7.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 311 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021-APRIL 2024)
    • 12.7.2 DEALS
    • TABLE 312 VACCINES MARKET: DEALS (JANUARY 2021-APRIL 2024)
    • 12.7.3 EXPANSIONS
    • TABLE 313 VACCINES MARKET: EXPANSIONS (JANUARY 2021-APRIL 2024)
    • 12.7.4 OTHER DEVELOPMENTS
    • TABLE 314 VACCINES MARKET: OTHER DEVELOPMENTS (JANUARY 2021-APRIL 2024)

13 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
  • 13.1 KEY PLAYERS
    • 13.1.1 GSK PLC
    • TABLE 315 GSK PLC: COMPANY OVERVIEW
    • FIGURE 45 GSK PLC: COMPANY SNAPSHOT (2023)
    • TABLE 316 GSK PLC: PRODUCTS OFFERED
    • TABLE 317 GSK PLC: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 318 GSK PLC: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 319 GSK PLC: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.2 MERCK & CO., INC.
    • TABLE 320 MERCK & CO., INC.: COMPANY OVERVIEW
    • FIGURE 46 MERCK & CO., INC.: COMPANY SNAPSHOT (2023)
    • TABLE 321 MERCK & CO., INC.: PRODUCTS OFFERED
    • TABLE 322 MERCK & CO., INC.: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 323 MERCK & CO., INC.: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 324 MERCK & CO., INC.: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.3 PFIZER INC.
    • TABLE 325 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2023)
    • TABLE 326 PFIZER INC.: PRODUCTS OFFERED
    • TABLE 327 PFIZER INC.: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 328 PFIZER INC.: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 329 PFIZER INC.: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.4 SANOFI
    • TABLE 330 SANOFI: COMPANY OVERVIEW
    • FIGURE 48 SANOFI: COMPANY SNAPSHOT (2023)
    • TABLE 331 SANOFI: PRODUCTS OFFERED
    • TABLE 332 SANOFI: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 333 SANOFI: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 334 SANOFI: EXPANSIONS (JANUARY 2020-MARCH 2024)
    • TABLE 335 SANOFI: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.5 CSL
    • TABLE 336 CSL: COMPANY OVERVIEW
    • FIGURE 49 CSL: COMPANY SNAPSHOT (2023)
    • TABLE 337 CSL: PRODUCTS OFFERED
    • TABLE 338 CSL: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 339 CSL: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 340 CSL: EXPANSIONS (JANUARY 2020-MARCH 2024)
    • TABLE 341 CSL: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.6 EMERGENT
    • TABLE 342 EMERGENT: COMPANY OVERVIEW
    • FIGURE 50 EMERGENT: COMPANY SNAPSHOT (2023)
    • TABLE 343 EMERGENT: PRODUCTS OFFERED
    • TABLE 344 EMERGENT: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 345 EMERGENT: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 346 EMERGENT: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.7 JOHNSON & JOHNSON SERVICES, INC.
    • TABLE 347 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW
    • FIGURE 51 JOHNSON & JOHNSON SERVICES INC.: COMPANY SNAPSHOT (2023)
    • TABLE 348 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS OFFERED
    • TABLE 349 JOHNSON & JOHNSON SERVICES INC.: PRODUCT APPROVALS (JANUARY 2020- MARCH 2024)
    • TABLE 350 JOHNSON & JOHNSON SERVICES INC.: DEALS (JANUARY 2020-MARCH 2024)
    • 13.1.8 ASTRAZENECA
    • TABLE 351 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 52 ASTRAZENECA: COMPANY SNAPSHOT (2023)
    • TABLE 352 ASTRAZENECA: PRODUCTS OFFERED
    • TABLE 353 ASTRAZENECA: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 354 ASTRAZENECA: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 355 ASTRAZENECA: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
    • TABLE 356 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW
    • TABLE 357 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED OVERSEAS)
    • TABLE 358 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA)
    • TABLE 359 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS LAUNCHES & APPROVALS TABLE 360 SERUM INSTITUTE OF INDIA PVT., LTD.: DEALS (JANUARY 2020-MARCH 2024)
    • 13.1.10 BAVARIAN NORDIC
    • TABLE 361 BAVARIAN NORDIC: COMPANY OVERVIEW
    • FIGURE 53 BAVARIAN NORDIC: COMPANY SNAPSHOT (2023)
    • TABLE 362 BAVARIAN NORDIC: PRODUCTS OFFERED
    • TABLE 363 BAVARIAN NORDIC: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 364 BAVARIAN NORDIC: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 365 BAVARIAN NORDIC: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
    • TABLE 366 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW
    • TABLE 367 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCTS OFFERED
    • TABLE 368 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 369 MITSUBISHI TANABE PHARMA CORPORATION: DEALS (JANUARY 2020-MARCH 2024)
    • 13.1.12 DAIICHI SANKYO COMPANY, LIMITED
    • TABLE 370 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
    • FIGURE 54 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)
    • TABLE 371 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED
    • TABLE 372 DAIICHI SANKYO COMPANY, LIMITED: DEALS (JANUARY 2020-MARCH 2024)
    • 13.1.13 PANACEA BIOTEC
    • TABLE 373 PANACEA BIOTEC: COMPANY OVERVIEW
    • FIGURE 55 PANACEA BIOTEC: COMPANY SNAPSHOT (2022)
    • TABLE 374 PANACEA BIOTEC: PRODUCTS OFFERED
    • TABLE 375 PANACEA BIOTEC: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 376 PANACEA BIOTEC: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.14 BIOLOGICAL E LIMITED
    • TABLE 377 BIOLOGICAL E LIMITED: COMPANY OVERVIEW
    • TABLE 378 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INDIAN MARKET)
    • TABLE 379 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET)
    • TABLE 380 BIOLOGICAL E LIMITED: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 381 BIOLOGICAL E LIMITED: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 382 BIOLOGICAL E LIMITED: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
    • 13.1.15 BHARAT BIOTECH
    • TABLE 383 BHARAT BIOTECH: COMPANY OVERVIEW
    • TABLE 384 BHARAT BIOTECH: PRODUCTS OFFERED (VACCINES)
    • TABLE 385 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 386 BHARAT BIOTECH: DEALS (JANUARY 2020-MARCH 2024)
    • 13.1.16 NOVAVAX
    • TABLE 387 NOVAVAX: COMPANY OVERVIEW
    • FIGURE 56 NOVAVAX: COMPANY SNAPSHOT (2023)
    • TABLE 388 NOVAVAX: PRODUCTS OFFERED (VACCINES)
    • TABLE 389 NOVAVAX: PRODUCT APPROVALS (JANUARY 2020-MARCH 2024)
    • TABLE 390 NOVAVAX: DEALS (JANUARY 2020-MARCH 2024)
    • 13.1.17 INOVIO PHARMACEUTICALS
    • TABLE 391 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW
    • FIGURE 57 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2023)
    • TABLE 392 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED (VACCINES)
    • TABLE 393 INOVIO PHARMACEUTICALS: DEALS (JANUARY 2020-MARCH 2024)
    • TABLE 394 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS (JANUARY 2020-MARCH 2024)
  • 13.2 OTHER PLAYERS
    • 13.2.1 SINOVAC
    • 13.2.2 INCEPTA PHARMACEUTICALS LTD.
    • 13.2.3 VALNEVA SE
    • 13.2.4 VBI VACCINE INC.
    • 13.2.5 BIO FARMA
    • 13.2.6 MICROGEN
    • 13.2.7 ZHI FEI BIOLOGICAL
    • 13.2.8 INDIAN IMMUNOLOGICALS LIMITED
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!